In partnership with the University of Texas Health Science Center at Houston, Cleveland biotechnology company Athersys Inc. (NASDAQ: ATHX) plans to conduct a Phase 2 clinical trial evaluating its MultiStem cell therapy for early treatment and prevention of complications after severe traumatic injury, according to a news release.
Click here to read the complete article. Story excerpt provided by Crain’s Cleveland Business. Written by Lydia Coutré. Originally published May 2, 2018.